OTCM
CANSF
Market cap2mUSD
May 13, Last price
0.02USD
1D
0.00%
1Q
6.81%
Jan 2017
400.00%
IPO
-81.65%
Name
Willow Biosciences Inc
Chart & Performance
P/E
—
P/S
0.87
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.30%
Rev. gr., 5y
299.45%
Revenues
5m
+297.78%
Net income
-6m
L-52.50%
CFO
-4m
L-65.91%
Earnings
Aug 11, 2025
Profile
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and varin cannabinoids, such as cannabigerovarin, cannabidivarin, and tetrahydrocannabivarin. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | |||||||||||
Revenues | 4,662 297.78% | 1,172 42.75% | 821 517.29% | ||||||||
Cost of revenue | 8,857 | 14,649 | 24,048 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (4,195) | (13,477) | (23,227) | ||||||||
NOPBT Margin | |||||||||||
Operating Taxes | 3 | (5) | 53 | ||||||||
Tax Rate | |||||||||||
NOPAT | (4,198) | (13,472) | (23,280) | ||||||||
Net income | (6,189) -52.50% | (13,029) -12.05% | (14,814) 141.27% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 1,910 | ||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | 970 | 731 | 632 | ||||||||
Long-term debt | 2,258 | 2,905 | 696 | ||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | 23 | ||||||||||
Net debt | 2,875 | 471 | (13,699) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (3,723) | (10,920) | (13,862) | ||||||||
CAPEX | (20) | (605) | (682) | ||||||||
Cash from investing activities | 78 | 3,465 | (4,553) | ||||||||
Cash from financing activities | 786 | (318) | (723) | ||||||||
FCF | (3,074) | (13,871) | (21,279) | ||||||||
| Balance | |||||||||||
Cash | 353 | 3,165 | 15,027 | ||||||||
Long term investments | |||||||||||
Excess cash | 120 | 3,106 | 14,986 | ||||||||
Stockholders' equity | (7,302) | (3,878) | 9,051 | ||||||||
Invested Capital | 8,768 | 9,470 | 8,010 | ||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 134,539 | 124,243 | 123,660 | ||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | (2,809) | (11,646) | (20,581) | ||||||||
EV/EBITDA | |||||||||||
Interest | 263 | 142 | 26 | ||||||||
Interest/NOPBT | |||||||||||